Plain-English translation of NCT04522544 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
The IMMUWIN trial is testing a new combination treatment for intermediate-stage hepatocellular carcinoma (liver cancer) that cannot be surgically removed. The combination includes two immune-boosting medications called and , which help your body's immune system fight cancer cells. These medications are paired with either a radiation-based procedure (Y-90 SIRT) or a catheter-based treatment (DEB-TACE) that directly targets tumors in the liver.
Currently, patients with intermediate-stage liver cancer have limited effective treatment options. Researchers believe that combining the new immune therapy with existing locoregional treatments may be more effective at controlling the cancer and improving survival compared to either approach alone.
If you qualify, you will be assigned to one of two treatment groups. One group will receive the radiation-based procedure combined with the two immune medications, while the other will receive a catheter-based procedure combined with the same immune medications. Throughout the trial, you will have regular visits for blood tests, imaging scans, and medical examinations to monitor how your cancer responds and how your body tolerates the treatment. The study involves close follow-up to assess both the safety and effectiveness of this new combination approach.
AI-generated summary from trial data · Jun 26, 2026 · Not medical advice
Germany